Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) has recently seen a significant increase in its stake by Strs Ohio, according to the company’s most recent disclosure with the Securities and Exchange Commission. Strs Ohio, an institutional investor, raised its stake in Y-mAbs Therapeutics by 35.4% during the first quarter of the year. This move resulted in Strs Ohio owning 148,800 shares of the company’s stock after acquiring an additional 38,900 shares during this period. As of its latest SEC filing, the institutional investor now owns 0.34% of Y-mAbs Therapeutics, translating to a worth of $745,000.
Y-mAbs Therapeutics revealed their quarterly earnings results on May 8th with impressive figures that surpassed market expectations. For this quarter, the company reported earnings per share (EPS) of ($0.15), outperforming the consensus estimate of ($0.31) by a substantial margin. This positive surprise reflected a $0.16 difference between projected and actual EPS figures.
The financial performance of Y-mAbs Therapeutics can be attributed to its robust revenue generation during this period as well. The company garnered $20.30 million in revenue for the quarter, significantly surpassing analyst estimates which were pegged at $15.55 million. Comparatively, this represented a remarkable 93.3% increase in quarterly revenue when compared to the same period last year.
It is noteworthy that even though Y-mAbs Therapeutics has exhibited strong growth in terms of financial indicators such as earnings per share and revenue, it continues to operate with a negative net margin of 98.48%. Nevertheless, these figures should be evaluated within the context of being a commercial-stage biopharmaceutical firm specializing in novel antibody-based therapeutic products for cancer treatment.
Y-mAbs Therapeutics’ flagship product offering is DANYELZA – a monoclonal antibody used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF). This treatment targets pediatric patients suffering from relapsed or refractory high-risk neuroblastoma, a type of cancer that affects the nervous system. The company remains dedicated to developing and commercializing such innovative therapeutic products aimed at combating cancer within the United States.
Looking ahead, industry analysts predict that Y-mAbs Therapeutics, Inc. will post earnings per share of -0.94 for the current year. As the company continues to evolve and expand its offering, it is expected to maintain its position as a leading player in the biopharmaceutical sector.
In conclusion, Strs Ohio’s increased stake in Y-mAbs Therapeutics highlights investor confidence in the company’s potential for growth and success within the biopharmaceutical market. Y-mAbs Therapeutics’ recent financial performance, including its impressive revenue generation and surpassing of earning estimates, further solidifies its standing as an innovator in cancer treatment therapies. With DANYELZA leading the way, Y-mAbs Therapeutics is poised to make significant strides in improving treatments for pediatric patients battling neuroblastoma and hold a prominent position within the healthcare industry.
[bs_slider_forecast ticker=”YMAB”]
the way for advancements in cancer treatment: Y-mAbs Therapeutics, Inc.
[stock_market_widget type=”chart” template=”basic” color=”#3946CE” assets=”YMAB” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” api=”yf”]July 24, 2023 – Y-mAbs Therapeutics, Inc: A Potential Game-Changer in the Fight Against Cancer
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company based in the United States, has recently caught the attention of several high-profile institutional investors. With its focus on the development and commercialization of novel antibody-based therapeutic products for the treatment of cancer, Y-mAbs Therapeutics is at the forefront of innovative advancements in cancer treatment.
Institutional investors such as Rice Hall James & Associates LLC and Swiss National Bank have both increased their stakes in Y-mAbs Therapeutics. Rice Hall James & Associates LLC now owns an impressive 90,375 shares of the company’s stock, valued at $1,074,000 after purchasing an additional 5,980 shares in the last quarter. Similarly, Swiss National Bank increased its stake by 8.2% and currently owns 62,000 shares worth $737,000.
JPMorgan Chase & Co. and MetLife Investment Management LLC have also recognized the potential of Y-mAbs Therapeutics and increased their positions in the company’s stock. JPMorgan Chase & Co. now holds 42,322 shares valued at $503,000 after acquiring an additional 4,752 shares this quarter. Meanwhile, MetLife Investment Management LLC’s position has grown by an impressive 54.2%, giving them ownership of 20,683 shares worth $246,000.
BlackRock Inc., one of the world’s largest investment management companies, saw significant value in Y-mAbs Therapeutics and increased its position by 6.4% during the first quarter. With over 2.9 million shares valued at $34,9860 million (about half of Ymabs’ market cap), BlackRock Inc.’s continued support further emphasizes investor confidence in this emerging biopharmaceutical company.
It is worth noting that 48.80% of Y-mAbs Therapeutics’ stock is owned by institutional investors, indicating a high level of trust and confidence in the company’s potential for growth and profitability.
In terms of the stock market performance, on Monday, Y-mAbs Therapeutics opened at $6.58 per share, with a market cap of $287.41 million. The price-to-earnings ratio stands at -3.89, indicating a degree of uncertainty but also showcasing its immense potential for growth. With a beta value of 0.70, the stock exhibits lower volatility compared to the overall market, making it an attractive investment opportunity.
Y-mAbs Therapeutics has experienced significant fluctuation in its stock price over the past twelve months, ranging from a low of $2.70 to a high of $20.48. However, it is important to note that historic prices do not guarantee future performance.
The company’s commitment lies in developing and commercializing novel antibody-based therapeutic products aimed at treating cancer. One such product is DANYELZA, a monoclonal antibody used in combination with granulocyte-macrophage colony-stimulating factor for pediatric patients with relapsed or refractory high-risk neuroblastoma.
Expert opinions on Y-mAbs Therapeutics have been varied among equities research analysts. Bank of America previously boosted their target price on the company’s shares from $6.00 to $12.00 in May 2023. Conversely, HC Wainwright decreased their target price from $19.00 to $11.00 but maintained their “buy” rating for the stock.
Guggenheim downgraded Y-mAbs Therapeutics from “buy” to “neutral,” while Wedbush upgraded the stock from “neutral” to “outperform,” raising their price target significantly from $5.00 to $13.00.
Canaccord Genuity Group, on the other hand, cut their price target from $20.00 to $18.00 but maintained a “buy” rating. Analyst coverage shows a diverse range of opinions, with two analysts giving the stock a “sell” rating, five suggesting a “hold,” and four proposing a “buy.” According to Bloomberg data, the consensus rating for Y-mAbs is currently “Hold,” with an average price target of $12.00.
On May 15th, Director Johan Wedell-Wedellsborg made headlines by purchasing over 101,740 shares at an average price of $9.65 per share. This transaction demonstrates the director’s confidence in the future prospects of Y-mAbs Therapeutics.
It is worth noting that insiders now hold 21.50% of the company’s stock, reiterating their belief in its potential growth and success.
As we look toward the promising future for Y-mAbs Therapeutics, it is clear that this commercial-stage biopharmaceutical company has captured the attention of significant institutional investors. With its innovative approach to cancer treatment and an impressive pipeline of therapeutic products under development, Y-mAbs Therapeutics is poised to make a significant impact in the fight against cancer. Investors are closely watching as this company continues to pave
